What question did this study set out to answer?

To investigate the effectiveness of GalNAc-modified lipid nanoparticles in delivering p65 siRNA to target NF-κB and alleviate liver injury from cytokine storms.

May 17, 2026Journal of Materials Chemistry B2 citationsOpen Access

GalNAc-modified five-component lipid nanoparticles for liver-targeted delivery of p65 siRNA to alleviate cytokine storm in liver injury via NF-κB targeting

ZLZhijie LiangGuangxi Medical University SLShaorong LiXi'an University of Science and Technology HHHuali HuangGuangxi Medical University

Key Points

To investigate the effectiveness of GalNAc-modified lipid nanoparticles in delivering p65 siRNA to target NF-κB and alleviate liver injury from cytokine storms.
Utilized GalNAc-modified five-component lipid nanoparticles for targeted delivery.
Administered p65 siRNA to assess its impact on NF-κB silencing and liver injury outcomes.
Evaluated the therapeutic effects on cytokine storm and acute liver injury.
Successful delivery of p65 siRNA to the liver demonstrated by reduced NF-κB activity.
Significant alleviation of cytokine storm observed in treated groups compared to controls.
Reduction in acute liver injury biomarkers correlating with targeted NF-κB silencing.

Abstract

GalNAc-modified five-component lipid nanoparticles enable liver-targeted delivery of p65 siRNA, effectively silencing NF-κB to alleviate cytokine storm and acute liver injury.

Demander à l'IA

Bookmark

View Full Paper